Table 124Relative risk of SCC in PUVA patients stratified by exposure level compared with the general population

ReferenceStandardised morbidity ratio
Population ratesPerson counts
STERN1984AAll incident tumours after ≥22 monthsAll incident tumours after ≥22 months
Low4.1 (2.3–6.8)Low2.2 (0.9–4.3)
Medium22.3 (13.5–34.1)Medium14.4 (7.6–24.6)
High(a)56.8 (42.7–74.2)High(a)31.6 (21.3–45.1)
STERN1988AAll incident tumours after ≥58 months
<1605.3 (3.6–7.6)
160–19925.5 (13.6–43.6)
200–25937.5 (23.5–56.7)
260+62.5 (35.0–103.1)
First tumour after ≥58 months
<1604.2 (2.6–6.4)
160–19922.2 (10.6–40.9)
200–25932.1 (18.7–51.4)
260+50.1 (24.9–89.5)
STERN1994Low10.6 (8.5–13.2)Low5.0 (3.6–6.9)
Medium23.6 (18.0–31.1)Medium13.4 (9.3–19.3)
High(a)83.0 (72.1–95.5)High(a)32.8 (26.2–41.0)
STERN1998A<1005.1 (3.5–7.2)
100–1598.4 (5.6–12.1)
160–33626.5 (22.2–31.4)
≥33768.5 (54.9–84.5)
Genital tumours
STERN1990Low17.5 (0.4–97.7)
Medium125.0 (15.1–451.5)
High285.7 (104.9–621.9)
STERN2002After May 1989(b)After May 1989(b)
Low44.4 (5.4–160.5)Low44.4 (5.4–160.5)
Medium36.1 (0.9–201.1)Medium36.1 (0.9–201.1)
High(a)168.7 (67.8–347-5)High(a)72.3 (14.9–211.3)
Total follow-upTotal follow-up
Low39.2 (10.7–100.4)Low29.4 (6.1–86.0)
Medium68.2 (14.1–199.3)Medium68.2 (14.1–199.3)
High(a)283.8 (175.7–433.8)High(a)148.6 (74.2–266.0)
a

Dose classification as high, medium or low was based on number of exposures and duration of treatment (i.e., a higher cumulative dose was required to classify as high dose at later follow-up times; see full classification table in Appendix Q)

From: 9, Phototherapy

Cover of Psoriasis
Psoriasis: Assessment and Management of Psoriasis.
NICE Clinical Guidelines, No. 153.
National Clinical Guideline Centre (UK).
Copyright © National Clinical Guideline Centre - October 2012.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.